BenevolentAI vs Biofourmis

Neither company has publicly disclosed a valuation, making a definitive size comparison difficult. BenevolentAI employs 100-500 people, while Biofourmis has 100-500 employees.

Biofourmis has raised more in total funding at $445M, compared to BenevolentAI's $292M — a gap of $153M.

Biofourmis holds the higher Awaira Score at 73/100, compared to BenevolentAI's 62/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 11-point gap that reflects meaningful differences in scale or traction.

BenevolentAI was founded by Joanna Shields in 2013. Biofourmis was founded by Kuldeep Singh in 2015. Visit each company's profile on Awaira for a full founder biography.

BenevolentAI: BenevolentAI applies machine learning to drug discovery, using knowledge graph technology and predictive AI models to identify novel drug candidates and repurpose existing compounds for new therapeutic applications. The London-based company has built a proprietary biomedical knowledge graph containing billions of data points extracted from scientific literature, clinical trial data, and genomic databases, which feeds its target identification and molecule generation pipelines.\n\nThe company went public on Euronext Amsterdam in 2022 via a SPAC merger with Odyssey Acquisition, having previously raised approximately $292 million in private funding from backers including SoftBank, Woodford Investment Management, and Mayfair Equity Partners. BenevolentAI has clinical-stage programs in atopic dermatitis and amyotrophic lateral sclerosis, developed from AI-generated hypotheses that were subsequently validated in wet lab experiments and progressed into human trials.\n\nBenevolentAI operates in the AI drug discovery sector alongside Recursion Pharmaceuticals, Exscientia, and Insilico Medicine. The company faces the inherent challenge of all computational drug discovery platforms in demonstrating that AI-generated candidates can survive clinical attrition at higher rates than traditionally discovered drugs. The platform is considered one of the more mature AI drug discovery systems in Europe, with the longest track record of moving AI-generated hypotheses into clinical development. Biofourmis: Biofourmis develops AI-powered digital therapeutics and remote patient monitoring technology that combines wearable biosensor data with machine learning models to predict clinical deterioration, monitor chronic disease progression, and support clinical trial digital endpoint measurement. The Singapore company platform processes continuous physiological data streams from patients in hospital-at-home programs, enabling earlier clinical intervention and reducing avoidable readmissions for heart failure, oncology, and post-surgical patients.\n\nThe company raised approximately $445 million including a Series D from investors including SoftBank Vision Fund 2, Openspace Ventures, and Mass General Brigham Ventures. Biofourmis has built partnerships with health systems including Brigham and Women Hospital, Guy Hospital, and several major Asian health systems for remote monitoring program deployment, and has entered into pharmaceutical partnerships for using its digital monitoring platform as a clinical trial measurement tool to capture digital endpoints.\n\nBiofourmis competes in the remote patient monitoring and digital therapeutics market against BioIntelliSense, Current Health, and Validic, as well as the monitoring capabilities of established medical device companies including Philips and Masimo that are adding AI analytics to their remote monitoring platforms. The hospital-at-home model, which uses continuous remote monitoring AI to substitute inpatient hospital stays for selected patient populations, represents a significant healthcare cost reduction opportunity that health systems in the US, UK, and Asia are actively piloting.

BenevolentAI was founded first in 2013, giving it 2 years of additional market experience. Biofourmis was founded later in 2015. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Both BenevolentAI and Biofourmis report similar employee counts of approximately 100-500. Team size is often a proxy for operational scale, though lean AI companies can punch well above their headcount.

Yes, BenevolentAI and Biofourmis are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.